Table 3.

Multivariate logistic regression analyses for positive molecular diagnoses

Clinical variables	Positive group	Negative group	Crude OR (95% CI)	P value	Adjusted OR (95%CI)a	P value
Overall: positive (n = 141) vs. negative (n = 315)
Bilateral stone	64%	17%	8.67 (5.51–13.64)	<0.001	3.49 (1.58–7.70)	0.002
Multiple stone	86%	29%	14.60 (8.58–24.85)	<0.001	8.46 (3.27–21.88)	<0.001
Nephrocalcinosis	14%	2%	7.50 (3.09–18.20)	0.015	5.05 (1.16–22.07)	0.031
Episode history	57%	29%	3.59 (2.36–5.47)	<0.001	4.04 (2.02–8.05)	<0.001
Subgroup 1: AGXT (n = 28) vs. negative (n = 315)
Bilateral stone	89%	17%	40.12 (11.69–137.67)	<0.001	43.66 (8.81–216.47)	<0.001
Nephrocalcinosis	32%	2%	20.77 (6.98–61.85)	0.009	16.52 (1.47–186.12)	0.023
Episode history	64%	29%	4.39 (1.95–9.88)	0.017	3.70 (1.14–11.95)	0.029
Subgroup 2: GRHPR (n = 16) vs. negative (n = 315)
Stone burden (continuous), cm	3.4 ± 2.0	1.6 ± 1.0	2.03 (1.50–2.74)	0.005	1.66 (1.06–2.58)	0.025
Episode history	69%	29%	8.95 (2.44–32.81)	0.012	7.09 (1.25–40.35)	0.027
Subgroup 3: HOGA1 (n = 34) vs. negative (n = 315)
Stone burden (continuous), cm	2.5 ± 1.5	1.6 ± 1.0	1.70 (1.32–2.18)	0.008	1.74 (1.08–2.80)	0.022
Subgroup 4: SLC3A1 (n = 26) vs. negative (n = 315)
Multiple stone	81%	29%	10.14 (3.71–27.69)	<0.001	13.02 (2.79–60.76)	0.001
Episode history	69%	29%	5.49 (2.31–13.07)	<0.001	7.47 (2.19–25.45)	0.001
Subgroup 5: SLC7A9 (n = 19) vs. negative (n = 315)
Bilateral stone	63%	17%	8.25 (3.11–21.9)	<0.001	9.28 (2.13–40.40)	0.003
Stone burden (continuous)–cm	3.0 ± 2.0	1.6 ± 1.0	1.97 (1.47–2.63)	0.028	1.49 (1.01–2.21)	0.046

BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio.

^aAdjusted for age, sex, BMI, geographic distribution, ethnicity, family history, eGFR, and urine culture status.